Palvella Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PVLA Nasdaq 2836 palvellatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Palvella Therapeutics, Inc.

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - Sep 28th, 2026 5:30 am
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer - Sep 9th, 2026 5:30 am
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences - Sep 2nd, 2026 5:30 am
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - Aug 31st, 2026 5:30 am
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital - Aug 26th, 2026 11:02 am
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands - Aug 16th, 2026 10:01 am
Palvella (PVLA) Q2 2026 Earnings Call Transcript - Aug 11th, 2026 11:16 am
Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval? - Aug 8th, 2026 5:10 am
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - Aug 5th, 2026 5:30 am
Palvella Therapeutics, Inc. Q2 2026 Earnings Call Summary - Aug 4th, 2026 4:52 pm
Palvella Therapeutics Inc (PVLA) (Q2 2026) Earnings Call Highlights: Strong Phase 3 Data and ... - Aug 4th, 2026 3:03 pm
Palvella Therapeutics Q2 Earnings Call Highlights - Aug 4th, 2026 11:04 am
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 4th, 2026 5:30 am
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing - Jul 30th, 2026 5:30 am
Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN - Jul 15th, 2026 8:01 am
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - Jun 30th, 2026 5:30 am
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - Jun 29th, 2026 5:30 am